JP2022538210A5 - - Google Patents
Info
- Publication number
- JP2022538210A5 JP2022538210A5 JP2021568727A JP2021568727A JP2022538210A5 JP 2022538210 A5 JP2022538210 A5 JP 2022538210A5 JP 2021568727 A JP2021568727 A JP 2021568727A JP 2021568727 A JP2021568727 A JP 2021568727A JP 2022538210 A5 JP2022538210 A5 JP 2022538210A5
- Authority
- JP
- Japan
- Prior art keywords
- day
- hyperammonemia
- preparation according
- pharmaceutical preparation
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962851339P | 2019-05-22 | 2019-05-22 | |
| US62/851,339 | 2019-05-22 | ||
| US16/851,999 | 2020-04-17 | ||
| US16/851,999 US20200368192A1 (en) | 2019-05-22 | 2020-04-17 | Treatment of hyperammonemia in patients with renal insufficiency |
| PCT/EP2020/064232 WO2020234431A1 (en) | 2019-05-22 | 2020-05-21 | Treatment of hyperammonemia in patients with renal insufficiency |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022538210A JP2022538210A (ja) | 2022-09-01 |
| JP2022538210A5 true JP2022538210A5 (https=) | 2023-05-29 |
Family
ID=73457942
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021568727A Pending JP2022538210A (ja) | 2019-05-22 | 2020-05-21 | 腎機能障害患者における高アンモニア血症の治療 |
Country Status (4)
| Country | Link |
|---|---|
| US (3) | US20200368192A1 (https=) |
| EP (1) | EP3972580A1 (https=) |
| JP (1) | JP2022538210A (https=) |
| WO (1) | WO2020234431A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11628143B1 (en) * | 2022-06-14 | 2023-04-18 | Novitium Pharma LLC | Tablet for oral suspension |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10064826B2 (en) * | 2013-03-15 | 2018-09-04 | Navinta, Llc | Direct compression and dry granulation processes for preparing carglumic acid tablets having less impurities than those produced by wet granulation process |
| EP3323410A1 (en) | 2016-11-22 | 2018-05-23 | RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.a. | Pharmaceutical parenteral formulation containing carglumic acid |
-
2020
- 2020-04-17 US US16/851,999 patent/US20200368192A1/en not_active Abandoned
- 2020-05-21 WO PCT/EP2020/064232 patent/WO2020234431A1/en not_active Ceased
- 2020-05-21 JP JP2021568727A patent/JP2022538210A/ja active Pending
- 2020-05-21 EP EP20725609.0A patent/EP3972580A1/en not_active Withdrawn
-
2021
- 2021-10-20 US US17/506,561 patent/US20220040129A1/en not_active Abandoned
- 2021-10-20 US US17/506,559 patent/US20220071938A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20090088913A (ko) | 개질된 방출형 진통 현탁제 | |
| JP2017066153A (ja) | Ｌ−オルニチンフェニル酢酸塩を用いる門脈圧亢進の治療及び肝機能の修復 | |
| CN102802412A (zh) | 用于治疗红细胞病症的方法及低剂量方案 | |
| WO2008122190A1 (en) | The composition comprising l-carnitine or derivatives thereof and its use | |
| CN1635872B (zh) | 前脂质体药物传递系统 | |
| JP2018513188A5 (https=) | ||
| TW200924757A (en) | Modified absorption formulation of gaboxadol | |
| JP2023552700A5 (https=) | ||
| JP2023115271A5 (https=) | ||
| JP7294807B2 (ja) | Ｌ－オルニチンフェニルアセテート製剤 | |
| JP2022538210A5 (https=) | ||
| JP6054871B2 (ja) | クレブス回路前駆体塩、特にクエン酸塩を含んでなる医薬組成物、及び医薬としてのこれらの使用 | |
| CA2362888C (en) | Use of r-aryl propionic acids for producing medicaments to treat diseases in humans and animals, whereby said diseases can be therapeutically influenced by inhibiting the activation of nf-kb | |
| JP2018502915A (ja) | 炎症及び疼痛の治療のための組成物及び方法 | |
| CN101754754B (zh) | 含有包覆的含药物的颗粒的可分散药片及其制备方法 | |
| JP2022177119A5 (https=) | ||
| US20090016984A1 (en) | Drug for Hyperphospheremia and Its Preparative Method | |
| JP2021506907A5 (https=) | ||
| JP2022019937A (ja) | ヒト又は動物の慢性若しくは急性のウイルス感染症及び／又は敗血症の予防若しくは治療のための組成物 | |
| ES2216050T3 (es) | Uso de l-carnitina y derivados para reducir niveles de ceramida y potenciar el efecto antiretroviral. | |
| CN110753540A (zh) | 瑞格列净的口服药物制剂 | |
| US20110117070A1 (en) | Compositions and methods for treating headache | |
| JPH0142927B2 (https=) | ||
| CN101884643A (zh) | 含有吡格列酮和肝素或低分子肝素的药物组合物的新用途 | |
| KR101633292B1 (ko) | 용법이 개선된 엔테카비어를 함유하는 약학적 조성물 |